Localization of αvβ6 integrin-TGF-β1/Smad3, mTOR and PPARγ in experimental colorectal fibrosis

European Journal of Histochemistry

Volumn 57, Issue 4, 2013, Pages 271-277

  Latella, Giovanni ^a   Vetuschi, A ^a   Sferra, R ^a   Speca, S ^a,b   Gaudio, E ^c  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b INSERM   (France)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

IBD; Integrins; Intestinal fibrosis; mTOR; PPAR; SMAD; TGF

Indexed keywords

ACTIN; ALPHAVBETA6 INTEGRIN; INTEGRIN; MTOR PROTEIN, MOUSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SMAD3 PROTEIN; SMAD3 PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID; TUMOR ANTIGEN;

ANIMAL; ARTICLE; COLON; DRUG EFFECT; FIBROSIS; GENETICS; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ACTINS; ANIMALS; ANTIGENS, NEOPLASM; COLON; FIBROSIS; INTEGRINS; MICE; PPAR GAMMA; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA1; TRINITROBENZENESULFONIC ACID;

EID: 84889595503     PISSN: 1121760X     EISSN: None     Source Type: Journal    
DOI: 10.4081/ejh.2013.e40     Document Type: Article

References (65)

1. Rieder F, Brenmoehl J, Leeb S, Scholmerich J, Rogler G. Wound healing and fibrosis in intestinal disease. Gut 2007;56:130-9.
2. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007;102:439-48.
3. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease-Current knowledge and future perspectives. J Crohns Colitis 2008;2:279-90.
4. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts I. Paracrine cells important in health and disease. Am J Physiol Cell Physiol 1999;277:C1-19.
5. Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000;279:G653-9.
6. Fiocchi C, Lund PK. Themes in fibrosis and gastrointestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2011; 300:G677-83.
7. Rieder F, Fiocchi C. Intestinal fibrosis in IBD-a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol 2009;6:228-35.
8. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
9. Speca S, Giusti I, Rieder R, Latella G. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol 2012;18:3635-61.
10. Mifflin RC, Pinchuk IV, Saada JI, Powell DW. Intestinal myofibroblasts: targets for stem cell therapy. Am J Physiol Gastrointest Liver Physiol 2011;300:G684-96.
11. Wipff PJ, Hinz B. Integrins and the activation of latent transforming growth factor beta1-An intimate relationship. Eur J Cell Biol 2008;87:601-15.
12. Jenkins G. The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol 2008;40:1068-78.
13. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-a family signalling. Nature 2003;425:577-84.
14. Roberts AB, Russo A, Felici A, Flanders KC. Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta. Ann NY Acad Sci 2003;995:1-10.
15. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001;305:285-98.
16. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010;11:97-105.
17. Margadant C, Monsuur HN, Norman JC, Sonnenberg A. Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol 2011;23:607-14.
18. Katsumoto TR, Violette SM, Sheppard D. Blocking TGFBBvia inhibition of the vvv6 integrin: a possible therapy for systemic sclerosis interstitial lung disease. Int J Rheumatol 2011;2011:208219.
19. Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z, et al. Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 2008;177:82-90.
20. Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 2008;177:56-65.
21. Hahm K, Lukashev ME, Luo Y, Yang WJ, Dolinski BM, Weinreb PH, et al. Alphav beta6 integrin regulates renal fibrosis and inflammation in Alport mouse. Am J Pathol 2007;170:110-25.
22. Nadler EP, Patterson D, Violette S, Weinreb P, Lewis M, Magid MS, et al. Integrin alphavbeta6 and mediators of extracellular matrix deposition are up-regulated in experimental biliary atresia. J Surg Res 2009;154:21-9.
23. Sullivan BP, Weinreb PH, Violette SM, Luyendyk JP. The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis. Am J Pathol 2010;177:2837-49.
24. Tsang CK, Qi H, Liu LF, Zheng XF. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 2007;12:112-24.
25. Wang S, Wilkes MC, Leof EB, Hirschberg R. Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis. Am J Physiol Renal Physiol 2010;298:F142-9.
26. Poulalhon N, Farge D, Roos N, Tacheau C, Neuzillet C, Michel L, et al. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent? J Biol Chem 2006;281:33045-52.
27. Osman B, Akool E-S, Doller A, Müller R, Pfeilschifter J, Eberhardt W. Differential modulation of the cytokine-induced MMP-9/TIMP-1 protease-antiprotease system by the mTOR inhibitor rapamycin. Biochem Pharmacol 2011;81:134-43.
28. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol 2009;20:2493-502.
29. Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, Whitsett JA, et al. Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2009;41:562-72.
30. Whaley-Connell A, Habibi J, Panfili Z, Hayden MR, Bagree S, Nistala R, et al. Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol 2011;34:115-25.
31. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006;45:786-96.
32. Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011;55:388-98.
33. Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, et al. Treatment with rapamycin prevents fibrosis in tightskin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010;62:2476-87.
34. Rousseaux C, Desreumaux P. The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARgamma and IBD). J Soc Biol 2006;200:121-31.
35. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 2006;350:385-91.
36. Zhang GY, Cheng T, Zheng MH, Yi CG, Pan H, Li ZJ, et al. Activation of peroxisome proliferator-activated receptor-gamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro. Arch Dermatol Res 2009;301:515-22.
37. Latella G, Vetuschi A, Sferra R, Zanninelli G, D'Angelo A, Catitti V, et al. Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis. Eur J Clin Invest 2009;39: 145-56.
38. Lakos G, Tacagawa S, Chen SJ, Ferreira AM, Han G, Wang XJ, et al. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 2004;165:203-17.
39. Zhao J, Shi W, Wang YL, Chen H, Bringas P, Datto MB, et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002;282:L585-93.
40. Inazaki K, Kanamaru Y, Kojima Y, Sueyoshi N, Okumura K, Kaneko K, et al. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int 2004;66:597-604.
41. Latella G, Vetuschi A, Sferra R, Catitti V, D'Angelo A, Zanninelli G, et al. Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamineinduced hepatic fibrosis in mice. Liver Int 2009;29:997-1009.
42. Flanders KC. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004; 85:47-64.
43. Zanninelli G, Vetuschi A, Sferra R, D'Angelo A, Fratticci A, Continenza MA, et al. Smad3 knock-out mice as a useful model to study intestinal fibrogenesis. World J Gastroenterol 2006;12:1211-8.
44. Verrecchia F, Chu ML, Mauviel A. Identification of novel TGF-b/smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001;276: 17058-62.
45. Tatler AL, Jenkins G. TGF-44activation and lung fibrosis. Proc Am Thorac Soc 2012;9:130-6.
46. Patsenker E, Popov Y, Stickel F, Jonczyk A, Goodman SL, Schuppan D. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008;135:660-70.
47. Chen G, Zhang L, Chen L, Wang H, Zhang Y, Bie P. Role of integrin Yvv6 in the pathogenesis of ischemia-related biliary fibrosis after liver transplantation. Transplantation 2013;95:1092-9.
48. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90.
49. Inoki K. Role of TSC-mTOR pathway in diabetic nephropathy. Diabetes Res Clin Pract 2008;82:S59-62.
50. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009;37:217-22.
51. Massey DC, Bredin F, Parkes M. Case report Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008;57:1294-6.
52. Dumortier J, Lapalus MG, Guillaud O, Poncet G, Gagnieu MC, Partensky C, et al. Everolimus for refractory Crohn's disease: a case report. Inflamm Bowel Dis 2008;14:874-7.
53. Lin Q, Fang LP, Zhou WW, Liu XM. Rosiglitazone inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts. Exp Lung Res 2010;36:120-8.
54. Tan X, Dagher H, Hutton CA, Bourke JE. Effects of PPAR gamma ligands on TGFbeta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 2010;11:21.
55. Kulkarni AA, Thatcher TH, Olsen KC, Maggirwar SB, Phipps RP, Sime PJ. PPARM ligands repress TGFl-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 2011;6:e15909.
56. Zhao C, Chen W, Yang L, Chen L, Stimpson SA, Diehl AM. PPARgamma agonists prevent TGFbeta1/Smad3-signaling in human hepatic stellate cells. Biochem Biophys Res Commun 2006;350:385-91.
57. Nan YM, Han F, Kong LB, Zhao SX, Wang RQ, Wu WJ, et al. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand J Gastroenterol 2011;46:358-69.
58. Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, et al. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycininduced skin fibrosis. Arthritis Rheum 2009;60:2822-9.
59. Wei J, Ghosh AK, Sargent JL, Komra K, Wu M, Huang QQ, et al. PPARMMdownregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010;5:e13778.
60. Yang L, Stimpson SA, Chen L, Wallace Harrington W, Rockey DC. Effectiveness of the PPARttagonist, GW570, in liver fibrosis. Inflamm Res 2010;59:1061-71.
61. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycininduced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009;174:519-33.
62. Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009;89:47-58.
63. Aoki Y, Maeno T, Aoyagi K, Ueno M, Aoki F, Aoki N, et al. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 2009;77:311-9.
64. Talukdar R, Tandon RK. Pancreatic stellate cells: new target in the treatment of chronic pancreatitis. J Gastroenterol Hepatol 2008;23:34-41.
65. Chen H, He YW, Liu WQ, Zhang JH. Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum. World J Gastroenterol 2008;14:2905-11.